Tables

Table 1: Summary of Cardiovascular Events at 4 year Follow-up in Women at Increased Cardiovascular Risk

	Placebo	Raloxifene 60mg/d	Raloxifene 120mg/d		
Total No	317	359	359	Relative risk 60mg/d	Relative risk 120mg/d
Any Cardiovascular event	41	28	28	0.6 (0.38-0.95)	0.6 (0.38-0.95)
Nonfatal	35	24	20	0.61 (0.37-0.99)	0.5 (0.30 – 0.85)
Fatal	7	4	8	0.5 (0.15-1.67)	1.01 (0.37-2.75)
Any coronary event	24	18	18	0.66 (0.37 −1.19)	0.66 (0.37-1.19)
Nonfatal	20	16	12	0.71 (0.37 − 1.34)	0.53 (0.27-1.05)
Fatal	4	2	6	0.44 (0.09-2.29)	1.32 (0.38-4.63)
Coronary death, MI, UA	20	18	16	0.79 (0.43 − 1.47)	0.71 (0.37 – 1.34)xfs
Any cerebrovascular event	17	10	10	0.52 (0.24 – 1.10)	0.52 (0.24 – 1.10)
Nonfatal	15	8	8	0.47 (0.21 − 1.07)	0.47 (0.21 – 1.07)
Fatal	3	2	2	0.59 (0.10 − 3.43)	0.59 (0.10 – 3.43)
All Strokes	14	6	6	0.38 (0.15 − 0.94)	0.38 (0.15 – 0.94)

Table 2 – Stage Distribution. Cancer of the Breast. (Thames Cancer registry).

Stage at detection	Percentage of breast cancer by age			
	50-59	60-69	70-79	80+
Local	46	45	41	37
Direct Extension	0	1	2	3
Local Nodes	25	22	18	7
Metastases	4	5	9	8
Not Known	26	27	30	45

Table 3 **Point estimates and corresponding sample sizes, for data describing the annual probability of the remaining cohort leaving the health state 'disease free interval'.**

Tamoxifen+ chemotherapy Year	1*		2*		3*		4*		5*		6*		7*	
[Pritchard et al, 1997]	0.930	352	0.076	327	0.113	303	0.057	268	0.135	253	0.191	219	0.107	177
[Gerard et al, 1993]	0.970	182	0.074	176	0.057	163	0.036	154	0.007	148	-	-	-	-
[Gelber et al, 1993]	0.924	341	0.103	315	0.149	283	0.081	241	0.095	221	0.057	200	0.086	189
[Jansen et al, 1998]	0.960	303	0.073	291	0.135	270	0.117	233	0.118	206	0.067	182	0.071	170
[Castiglione-Gertsch et al, 1994]	0.887	97	0.137	86	0.123	74	0.042	65	0.087	62	0.064	57	0.034	53
Year	8		9		10		11		12		13		14	
[Pritchard et al, 1997]	0.168	158	0.029	132	-	-	-	-	-	-	-	-	-	-
[Gerard et al, 1993]	-	-	-	-	-	-	-	-	-	-	-	-	-	-
[Gelber et al, 1993]	-	-	-	-	-	-	-	-	-	-	-	-	-	-
[Jansen et al, 1998]	0.058	158	0.061	148	0.130	139	0.025	121	0.000	118	-	-	-	-
[Castiglione-Gertsch et al, 1994]	0.124	52	0.081	45	0.033	41	0.011	40	0.023	40	0.023	39	0.000	38

From Karnon J. Economic Evaluation of health care technologies: a comparison of alternative modelling techniques.
Phd thesis, brunel University, March 2001

Table 4:   **The incidence of breast cancer in the average female population, in women with osteoporosis and women at the threshold for osteoporosis**

Age (Years)	Incidence of breast cancer within subsets of the population.		
	Average population	Population with average BMD values	Population at the threshold for osteoporosis
50-54	0.245%	0.252%	0.135%
55-59	0.278%	0.289%	0.170%
60-64	0.319%	0.336%	0.217%
65-69	0.257%	0.272%	0.191%
70-74	0.269%	0.288%	0.219%
75-79	0.284%	0.304%	0.250%
80-84	0.320%	0.337%	0.301%
85-89	0.362%	0.373%	0.353%

Table 5: The cost-effectiveness of Raloxifene: "single-risk" population.

Age (Years)	Model	Marginal Costs (£)	Marginal QALYs	Cost per QALY (£)	90% CI Lower	Upper
50	1	144738	0.58	261865	188462	369212
	2	141751	5.51	26292	21350	34259
	3	138038	5.93	23747	19450	30381
60	1	141810	0.69	217062	156147	306074
	2	138948	4.19	33859	27684	44174
	3	135611	4.59	30031	24981	38261
70	1	128761	1.81	75465	53789	107327
	2	126097	3.85	33318	27634	41363
	3	122792	4.26	29222	24459	35875
80	1	109802	0.90	129135	90392	185801
	2	107453	1.65	66745	52363	86690
	3	103998	2.06	51409	41918	64489

Note: Model 1 = Vertebral fractures only, Model 2 = including breast cancer, model 3 = including breast cancer and CVD.

Table 6: The cost-effectiveness of Raloxifene: "Double-risk" population.

Age (Years)	Model	Marginal Costs (£)	Marginal QALYs	Cost per QALY (£)	90% CI Lower	Upper
50	1	142735	1.41	107422	76922	152033
	2	139770	6.30	22613	18536	29181
	3	136056	6.71	20609	17144	26062
60	1	140113	1.38	107297	76873	151797
	2	137246	4.88	28615	23472	35952
	3	133909	5.29	25720	21400	31890
70	1	120461	3.62	35393	24833	50877
	2	117808	5.65	21343	16806	27844
	3	114503	6.06	19277	15409	24713
80	1	99599	1.81	58893	39668	87012
	2	97242	2.56	39284	28906	53854
	3	93788	2.96	32432	24625	43089

Note: Model 1 = Vertebral fractures only, Model 2 = including breast cancer, model 3 = including breast cancer and CVD.